Context Therapeutics Inc. (NASDAQ:CNTX) Shares Sold by Affinity Asset Advisors LLC

Affinity Asset Advisors LLC decreased its stake in Context Therapeutics Inc. (NASDAQ:CNTX - Free Report) by 23.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,015,340 shares of the company's stock after selling 305,813 shares during the period. Affinity Asset Advisors LLC owned approximately 1.35% of Context Therapeutics worth $1,066,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. State Street Corp boosted its stake in shares of Context Therapeutics by 21.5% during the 3rd quarter. State Street Corp now owns 111,907 shares of the company's stock worth $219,000 after acquiring an additional 19,800 shares in the last quarter. Franklin Resources Inc. purchased a new stake in Context Therapeutics during the third quarter worth $3,689,000. Y Intercept Hong Kong Ltd acquired a new stake in Context Therapeutics in the third quarter valued at $89,000. Landscape Capital Management L.L.C. purchased a new position in shares of Context Therapeutics in the fourth quarter valued at $94,000. Finally, Clear Harbor Asset Management LLC boosted its position in shares of Context Therapeutics by 60.6% in the 4th quarter. Clear Harbor Asset Management LLC now owns 57,804 shares of the company's stock worth $61,000 after buying an additional 21,804 shares in the last quarter. 14.03% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have weighed in on the stock. Citizens Jmp upgraded shares of Context Therapeutics to a "strong-buy" rating in a report on Wednesday, January 8th. HC Wainwright reaffirmed a "buy" rating and issued a $5.00 target price on shares of Context Therapeutics in a research note on Friday, March 21st. D. Boral Capital reissued a "buy" rating and set a $9.00 price target on shares of Context Therapeutics in a research report on Wednesday, April 9th. Finally, JMP Securities assumed coverage on Context Therapeutics in a research report on Wednesday, January 8th. They issued an "outperform" rating and a $4.00 price objective on the stock. Six equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Context Therapeutics currently has a consensus rating of "Buy" and an average price target of $6.17.

Context Therapeutics Price Performance

CNTX traded down $0.02 during trading on Friday, hitting $0.84. The company's stock had a trading volume of 45,589 shares, compared to its average volume of 407,430. Context Therapeutics Inc. has a twelve month low of $0.55 and a twelve month high of $2.75. The stock has a market cap of $75.63 million, a PE ratio of -0.93 and a beta of 2.18. The firm's 50 day moving average price is $0.77 and its 200-day moving average price is $1.23.

Context Therapeutics (NASDAQ:CNTX - Get Free Report) last released its earnings results on Thursday, March 20th. The company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.05) by $0.01. Equities analysts anticipate that Context Therapeutics Inc. will post -0.51 earnings per share for the current year.

Context Therapeutics Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.